Clinical significance and immunogenomic landscape analyses of the immune cell signature based prognostic model for patients with breast cancer

Abstract Breast cancer is one of the most common types of cancers and the leading cause of death from malignancy among women worldwide. Tumor-infiltrating lymphocytes are a source of important prognostic biomarkers for breast cancer patients. In this study, based on the tumor-infiltrating lymphocyte...

Full description

Saved in:
Bibliographic Details
Published in:Briefings in bioinformatics 2021-07, Vol.22 (4)
Main Authors: Wang, Shiyuan, Xiong, Yuqiang, Zhang, Qi, Su, Dongqing, Yu, Chunlu, Cao, Yiyin, Pan, Yi, Lu, Qianzi, Zuo, Yongchun, Yang, Lei
Format: Article
Language:English
Subjects:
Biomarkers
Breast cancer
Chemotherapy
Clinical significance
Decision making
Genomics
Immune checkpoint
Immune system
Immunotherapy
Lymphocytes
Malignancy
Microenvironments
Nomograms
Patients
Risk
Training
Tumor-infiltrating lymphocytes
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Breast cancer is one of the most common types of cancers and the leading cause of death from malignancy among women worldwide. Tumor-infiltrating lymphocytes are a source of important prognostic biomarkers for breast cancer patients. In this study, based on the tumor-infiltrating lymphocytes in the tumor immune microenvironment, a risk score prognostic model was developed in the training cohort for risk stratification and prognosis prediction in breast cancer patients. The prognostic value of this risk score prognostic model was also verified in the two testing cohorts and the TCGA pan cancer cohort. Nomograms were also established in the training and testing cohorts to validate the clinical use of this model. Relationships between the risk score, intrinsic molecular subtypes, immune checkpoints, tumor-infiltrating immune cell abundances and the response to chemotherapy and immunotherapy were also evaluated. Based on these results, we can conclude that this risk score model could serve as a robust prognostic biomarker, provide therapeutic benefits for the development of novel chemotherapy and immunotherapy, and may be helpful for clinical decision making in breast cancer patients.
ISSN:1467-5463
1477-4054
DOI:10.1093/bib/bbaa311